メニュー

  1. 国立循環器病研究センター 研究所 TOP
  2. 各部のご紹介
  3. 血管生理学部
  4. 業績

血管生理学部

業績

主要な研究業績

  1. Ishibashi T, Inagaki K, Okazawa M, Yamagishi A, Ohta-Ogo K, Asano R, Masaki T, Kotani Y, Ding X, Chikaishi-Kirino T, Maedera N, Shirai M, Hatakeyama K, Kubota Y, Kishimoto T, Nakaoka Y. IL-6/gp130 signaling in CD4+ T cells drives the pathogenesis of pulmonary hypertension. Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2315123121.doi: 10.1073/pnas.2315123121. 
  2. Arita Y, Ishibashi T, Nakaoka Y. Current Immunosuppressive Treatment for Takayasu Arteritis. Circulation Journal. 2023 Dec 19. doi: 10.1253/circj.CJ-23-0780.
  3. Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, Isobe M, Harigai M. Organ Damage and Quality of Life in Takayasu Arteritis: Evidence from a National Registry Analysis. Circulation Journal. 2024 Feb 22;88(3):285-294. doi: 10.1253/circj.CJ-23-0656. Epub 2023 Dec 19.
  4. Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Mod Rheumatol. 2023 Jul 31:road074. doi: 10.1093/mr/road074. Online ahead of print.
  5. Manabe Y, Ishibashi T, Asano R, Tonomura S, Maeda Y, Motooka D, Ueda J, Yanagawa M, Edamoto-Taira Y, Chikaishi-Kirino T, Masaki T, Inagaki T, Nakamura S, Katada Y, Okazawa M, Narazaki M, Ogo T, Kumanogoh A, Nakaoka Y*. Gut Dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis. Arthritis Res Ther. 2023. 25(1); 46; doi:10.1186/s13075-023-03031-9.
  6. Konagai N, Kamiya CA, Nakanishi A, Iwanaga N, Sawada M, Kakigano A, Kanagawa T, Eto S, Nishida Y, Nakaoka Y, Yoshimatsu J. Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies. RMD Open. 2023 Feb;9(1):e002996. doi: 10.1136/rmdopen-2023-002996.
  7. Konda N, Sakai R, Saeki K, Matsubara Y, Nakamura Y, Miyamae T, Nakaoka Y, Harigai M. Nationwide clinical and epidemiological study of large-vessel vasculitis in Japan in 2017. Mod Rheumatol.2023 Feb 4:road019. doi: 10.1093/mr/road019.
  8. Ishibashi T, and Nakaoka Y. Biomarkers for Takayasu arteritis: Which is the most promising？Int J Cardiol.2023　Jan 15; 371: 418-419
  9. Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y*,Takeuchi O*. Regnase-1 prevents pulmonary arterial hypertension via mRNA degradation of Interleukin-6 and Platelet-Derived Growth Factor in alveolar macrophages.  2022 Sep 27;146(13):1006-1022 (*equal contribution, *co-correspondence)
  10. Harigai M, Miyamae T, Hashimoto H, Yoshida A, Yamashita K, Nakaoka Y.A Multicentre, Large-Scale, Observational Study of Tocilizumab in Patients with Takayasu Arteritis in Japan: The ACT-Bridge Study. Mod Rheumatol. 2022 Sep 3; roac099. doi:0.1093/mr/roac099.
  11. Sugihara T, Nakaoka Y, Uchida HA, Yoshifuji H, Maejima Y, Watanabe Y, Amiya E, Tanemoto K, Miyata T, Umezawa N, Manabe Y, Ishizaki J, Shirai T, Nagafuchi H, Hasegawa H, Miyamae T, Niiro H, Ito S, Ishii T, Isobe M, Harigai M.Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis: Results of a Delphi Exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis.
    Mod Rheumatol. 2022 Aug 20;32(5):930-937. doi: 10.1093/mr/roab081.
  12. Sugihara T, Nakaoka Y, Uchida HA, Yoshifuji H, Maejima Y, Watanabe Y, Amiya E, Tanemoto K, Miyata T, Umezawa N, Manabe Y, Ishizaki J, Shirai T, Nagafuchi H, Hasegawa H, Miyamae T, Niiro H, Ito S, Ishii T, Isobe M, Harigai M. Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis: Results of a Delphi Exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis. Mod Rheumatol. 2021 Nov 27:roab081. doi: 10.1093/mr/roab081.
  13. Nakaoka Y*, Yanagawa M, Hata A, Yamashita K, Okada N, Yamakido S, Hayashi H, Jayne D. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford). 2022 May 30; 61(6):2360-2368. doi: 10.1093/rheumatology/keab684.
  14. Masaki T, Okazawa M, Asano R, Inagaki T, Ishibashi T, Yamagishi A, Mizushima S, Nishimura M, Manabe Y,Ishibashi-Ueda H, Shirai M, Tsuchimochi H, Pearson JT, Kumanogoh A, Sakata Y, Ogo T, Kishimoto T, Nakaoka Y. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 118(11):e2023899118, 2021
  15. Inagaki T, Pearson JT, Tsuchimochi H, Schwenke DO, Saito S, Higuchi T, Masaki T, Umetani K, Shirai M, Nakaoka Y. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography. Am J Physiol Heart Circ Physiol.2021 Mar 1; 320(3):H1021-H1036.　doi:10.1152/ajpheart.00327.2020. Epub 2021 Jan 22.
  16. Arita Y, Nakaoka Y, Eda Y, Kitabayashi K, Hasegawa S. Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab. JACC: Case Reports2020 Dec, 2(15); 2363-2367. doi:10.1016/j.jaccas.2020.07.039
  17. Watanabe Y, Miyata T, Shigematsu K, Tanemoto K, Nakaoka Y, Harigai M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). Current Trends in Epidemiology and Clinical Features of Thromboangiitis Obliterans in Japan - A Nationwide Survey Using the Medical Support System Database. Circ J. 2020 Sep 25;84(10):1786-1796.
  18. Mori H, Ishibashi T, Inagaki T, Okazawa M, Masaki T, Asano R, Manabe Y, Ohta-Ogo K, Narazaki M, Ishibashi-Ueda H, Kumanogoh A, Nakaoka Y. Pristane/Hypoxia (PriHx) Mouse as a Novel Model of Pulmonary Hypertension Reflecting Inflammation and Fibrosis. Circ J. 2020 Jun 25;84(7):1163-1172.
  19. Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS).Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther. 2020 Apr 7;22(1):72.
  20. Minato T, Nirasawa S, Sato T, Yamaguchi T, Hoshizaki M, Inagaki T, Nakahara K, Yoshihashi T, Ozawa R, Yokota S, Natsui M, Koyota S, Yoshiya T, Yoshizawa-Kumagaye K, Motoyama S, Gotoh T, Nakaoka Y, Penninger JM, Watanabe H, Imai Y, Takahashi S, Kuba K. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. Nat Commun. 2020 Feb 26;11(1):1058. doi: 10.1038/s41467-020-14867-z
  21. Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Komagata Y, Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigai M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, Wada T, Inoue Y, Uchida HA, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada KE, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugiyama H, Takeno M, Tamura N, Tsutsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Takihara K, Murohara T, Momomura SI; JCS Joint Working Group. JCS 2017 Guideline on Management of Vasculitis Syndrome　- Digest Version. Circ J. 2020 Jan 24;84(2):299-359. doi: 10.1253/circj.CJ-19-0773.
  22. Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, and Nishimoto N. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomised controlled phase 3 TAKT study. Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434. doi: 10.1093/rheumatology/kez630.
  23. Park HS, Kim HZ, Park JS, Lee J, Lee SP, Kim H, Ahn CW, Nakaoka Y, Koh GY, Kang S. Beta Cell-Derived Angiopoietin-1 Regulates Insulin Secretion and Glucose Homeostasis by Stabilizing Islet Microenvironment. 2019 Apr;68(4):774-786. doi: 10.2337/db18-0864. Epub 2019 Feb 6.
  24. Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc Natl Acad Sci U S A.2018 Dec 18;115(51):13045-13050. doi: 10.1073/pnas.1808850115. Epub 2018 Nov 29.
  25. Pearson JT, Collie N, Lamberts RR, Inagaki T, Yoshimoto M, Umetani K, Davis P, Wilkins G, Jones PP, Shirai M, Schwenke DO. Ghrelin Preserves Ischemia-Induced Vasodilation of Male Rat Coronary Vessels Following β-Adrenergic Receptor Blockade. 2018; 159, 1763-1773.
  26. Kim KH, Nakaoka Y, Augustin HG, Koh GY. Myocardial Angiopoietin-1 Controls Atrial Chamber Morphogenesis by Spatiotemporal Degradation of Cardiac Jelly. Cell Reports, 23, 2455-2466, May 22, 2018
  27. Nakaoka Y*. Response to: 'Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis' by Lee and Song. Ann Rheum Dis.2018 Feb 10. pii: annrheumdis-2017-212871. doi: 10.1136/annrheumdis-2017-212871.
  28. Nakaoka Y*, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).Ann Rheum Dis. 2018 Mar; 77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30. (*corresponding author)
  29. Yasui T, Masaki T, Arita Y, Ishibashi T, Inagaki T, Okazawa M, Oka T, Shioyama W, Yamauchi-Takihara K, Komuro I, Sakata Y, Nakaoka Y*. Molecular Characterization of Striated Muscle-specific Gab1 Isoform as a Critical Signal Transducer for Neuregulin-1/ErbB Signaling in Cardiomyocytes. PLoS One.2016 Nov 18;11(11):e0166710. doi: 10.1371/journal.pone.0166710　 (*corresponding author)
  30. Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y, He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I, Koh GY.　Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med.2016 Apr 20;8(335):335ra55. doi: 10.1126/scitranslmed.aad9260.9.
  31. Inagaki T, Akiyama T, Du CK, Zhan DY, Yoshimoto M, Shirai M. Monoamine oxidase-induced hydroxyl radical production and cardiomyocyte injury during myocardial ischemia-reperfusion in rats. Free Radic Res. 2016 Jun;50(6):645-53.
  32. Okazawa M, Abe H, Nakanishi S.　The Etv1 transcription factor activity-dependently downregulates a set of genes controlling cell growth and differentiation in maturing cerebellar granule cells. Biochem Biophys Res Commun.2016 May 13;473(4):1071-7.
  33. Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takihara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y. * Interleukin-6/interleukin-21-signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A.2015 May 19; 112(20): E2677-86. doi: 10.1073/pnas.1424774112. Epub 2015 May 4. (*corresponding author)
  34. Arita Y, Nakaoka Y*, Otsuki M, Higuchi K, Hashimoto-Kataoka T, Yasui T, Masaki T, Ohtani T, Kishimoto T, Yamauchi-Takihara K, Komuro I, Sakata Y. Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. Int J Cardiol.187:319-321, 2015. (*corresponding author)
  35. Furuta K, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Maeda S, Egawa M, Chatani N, Nishida K, Nakaoka Y, Kiso S, Kamada Y, Takehara T. Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice. 2016 Apr;63(4):1340-55. doi: 10.1002/hep.28410. Epub 2016 Jan 22.
  36. Terao C, Matsumura T, Yoshifuji H, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakaymada S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Omura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F. Takayasu arteritis and ulcerative colitis-high concurrence ratio and genetic overlap.Arthritis & Rheumatol. 2015 May; 67(8): 2226-2232. doi: 10.1002/art.39157.
  37. Cherif M., Caputo M, Nakaoka Y, Angelini G, Ghorbel M. Gab1 Is Modulated by Chronic Hypoxia in Children with Cyanotic Congenital Heart Defect and Its Overexpression Reduces Apoptosis in Rat Neonatal Cardiomyocytes. BioMed Research International. 2015 (2015), Article ID 718492 (8 pages)
  38. Kizu T, Yoshida Y, Furuta K, Ogura S, Egawa M, Chatani N, Hamano M, Takemura T, Ezaki H, Kamada Y, Nishida K, Nakaoka Y, Kiso S, Takehara T. Loss of Gab1 adaptor protein in hepatocytes aggravates experimental liver fibrosis in mice. Am J Physiol Gastrointest Liver Physiol.308(7):G613-24, 2015. doi: 10.1152/ajpgi.00289.2014. Epub 2015 Jan 23
  39. Arita Y, Nakaoka Y*, Matsunaga T, Kidoya H, Yamamizu K, Arima Y, Hashimoto-Kataoka T, Ikeoka K, Yasui T, Masaki T, Yamamoto K, Higuchi K, Park JS, Shirai M, Nishiyama K, Yamagishi H, Otsu K, Kurihara H, Minami T, Yamauchi-Takihara K, Koh GY, Mochizuki N, Takakura N, Sakata Y, Yamashita JK, Komuro I. Myocardium-derived angiopoietin-1 is essential for coronary vein formation in the developing heart. Nat Commun.2014 Jul 29; 5: 4552. doi: 10.1038/ncomms5552. (*corresponding author)
  40. Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, Shioi G, Chang W, Suda T, Mochizuki N, Nakaoka Y, Komuro I, Yoo OJ, Koh GY. Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy. Sci Transl Med.2013 Sep 18; 5(203): 203ra127. doi: 10.1126/scitranslmed.3006666.
  41. Nakaoka Y*, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, Yasui T, Ikeoka K, Ohtani T, Sakata Y, Shima Y, Kumanogoh A, Yamauchi-Takihara K, Tanaka T, Kishimoto T, Komuro I. Tocilizumab for the Treatment of the Patients with Refractory Takayasu Arteritis. Int Heart J. 54, 406-411, 2013 (*corresponding author)
  42. Rodriguez-Araujo G, Nakagami H, Hayashi H, Mori M, Shiuchi T, Minokoshi Y, Nakaoka Y, Takami Y, Komuro I, Morishita R, Kaneda Y. Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway. Cell Mol Life Sci. 70(6):1123-33, 2013. Epub 2012 Nov 3.
  43. Nakaoka Y*, Komuro I. Gab docking proteins in cardiovascular disease, cancer, and inflammation.Int J Inflam. 2013;2013:141068. doi: 10.1155/2013/141068. Epub 2013 Jan 22. (*corresponding author)
  44. Higuchi K, Nakaoka Y*, Shioyama W, Arita Y, Hashimoto T, Yasui T, Ikeoka K, Kuroda T, Minami T, Nishida K, Fujio Y, Yamauchi-Takihara K, Shirai M, Mochizuki N, Komuro I*. Endothelial Gab1 deletion accelerates angiotensin II-dependent vascular inflammation and atherosclerosis in apolipoprotein E knockout mice.Circ J. 76(8):2031-40, 2012. Epub 2012 May 19. (*co-corresponding author)
  45. Shioyama W, Nakaoka Y*, Higuchi K, Minami T, Nishida K, Taniyama Y, Kidoya H, Arita Y, Hashimoto T, Fujio Y, Shirai M, Takakura N, Morishita R, Yamauchi-Takihara K, Kodama T, Hirano T, Mochizuki N, Komuro I*. Gab1 is essential for postnatal angiogenesis via hepatocyte growth factor/c-Met signaling. Circ Res. 108, 664-675, 2011. Epub 2011 Feb 3 (*co-corresponding author)
  46. Nakaoka Y*, Shioyama W, Kunimoto S, Arita Y, Higuchi K, Yamamoto K, Fujio Y, Nishida K, Kuroda T, Hirota H, Yamauchi-Takihara K, Komuro I, Mochizuki N. SHP2 mediates gp130-dependent cardiomyocyte hypertrophy via negative regulation of skeletal alpha-actin gene. J Mol Cell Cardiol. 49: 157-164, 2010 (*corresponding author)
  47. Wang D, Paria BC, Zhang Q, Karpurapu M, Li Q, Gerthoffer WT, Nakaoka Y, Rao GN. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injury-induced restenosis. Circ Res. 104:1066-75, 2009
  48. Koyama T, Nakaoka Y*, Fujio Y, Hirota H, Nishida K, Sugiyama S, Okamoto K, Yamauchi-Takihara K, Yoshimura M, Mochizuki S, Hori M, Hirano T, Mochizuki N. Interaction of Scaffolding Adaptor Protein Gab1 with Tyrosine Phosphatase SHP2 Negatively Regulates IGF-I-dependent Myogenic Differentiation via the ERK1/2 Signaling Pathway.J Biol Chem. 283: 24234-24244, 2008 (*corresponding author, co-first author)
  49. Nakaoka Y*, Nishida K, Narimatsu M, Kamiya A, Minami T, Sawa H, Okawa K, Fujio Y, Koyama T, Maeda M, Sone M, Yamasaki S, Arai Y, Koh GY, Kodama T, Hirota H, Otsu K, Hirano T, and Mochizuki N*. Gab family proteins are essential for postnatal maintenance of cardiac function through transmitting neuregulin-1/ErbB signaling. J Clin Invest.117: 1771-1781, 2007 (*co-corresponding author)
  50. Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai T, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K, Hirano T, Kawase I, Hirota H. Activation of gp130 Transduces Hypertrophic Signal Through Interaction of Scaffolding Docking Protein Gab1 With Tyrosine Phosphatase SHP2 in Cardiomyocytes. Circ Res. 93: 221-229, 2003

過去の業績

最終更新日：2024年05月27日

各部の紹介About

設定メニュー